Panacea Biotec Limited (PANACEABIO) AI Stock Analysis

Panacea Biotec Limited

(NSE:PANACEABIO)

Select Model

Rating:47.1Neutral

Price Target:INR 308.00▼(-1.58% Downside)

Action:reiterated

Date:09/11/26

The stock earns a cautious score of 47.1 because weak and volatile profitability together with a poor cash flow record outweigh the strength of a deleveraged, equity-rich balance sheet. Persistent losses and historically negative free cash flows signal execution and sustainability risks, while current price action shows a soft, mildly bearish trend with above-market volatility. Valuation signals are also unattractive, with a deeply negative P/E and no dividend to compensate for the higher risk profile.

Positive Factors

Revenue GrowthMeaningful revenue recovery since FY2023 indicates improved commercial activity and product demand across the business. If maintained, this expanding revenue base can support operating leverage, broader market reach, and eventual progress toward more sustainable earnings.

Negative Factors

Persistent UnprofitabilityRevenue growth has not yet translated into dependable operating or net earnings, showing that the business model remains economically challenged. Continued losses can constrain internal reinvestment, weaken returns on equity, and delay the compounding of shareholder value even as sales recover.

Panacea Biotec Limited (PANACEABIO) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 19.19B
Dividend Yield: ―
Average Volume (3M): 5,932
Price to Earnings (P/E): -270.0
Beta (1Y): 1.25
Revenue Growth: 10.26%
EPS Growth: -162.02%
Country: India
Employees: 2,102
Sector: General
Sector Strength: 55
Industry: Biotechnology

Panacea Biotec Limited Business Overview & Revenue Model

Company Description

Established in 1984 and headquartered in New Delhi, India, Panacea Biotec Limited is a biotechnology company dedicated to the innovation, production, and commercialization of pharmaceuticals, vaccines, and biosimilars. Its primary market is India, wi...

How the Company Makes Money

Panacea Biotec makes money primarily by selling pharmaceutical products and vaccines/biologics-related products. Key revenue streams typically include: (1) product sales of finished-dose pharmaceutical formulations (such as branded/generic prescripti...

Panacea Biotec Limited Financial Statement Overview

Summary

Recovering revenue and very low leverage support balance sheet strength, but recurring net losses and mostly negative free cash flow keep overall financial quality only moderate.

Income Statement

46Neutral

Balance Sheet

72Positive

Cash Flow

39Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	6.73B	6.40B	5.59B	5.52B	4.57B	6.59B
Gross Profit	2.12B	1.45B	3.60B	446.53M	1.78B	3.42B
EBITDA	112.90M	-46.60M	307.40M	417.69M	563.65M	16.74B
Net Income	-71.20M	-53.70M	-83.70M	-11.73M	-332.37M	10.78B
Balance Sheet
Total Assets	0	12.62B	12.90B	12.41B	12.71B	17.59B
Cash, Cash Equivalents and Short-Term Investments	744.00M	744.00M	1.79B	1.56B	2.13B	5.52B
Total Debt	0	236.60M	222.10M	209.90M	202.19M	341.55M
Total Liabilities	-8.29B	4.33B	4.59B	4.02B	4.31B	8.85B
Stockholders Equity	8.29B	8.35B	8.35B	8.42B	8.44B	8.77B
Cash Flow
Free Cash Flow	-260.70M	-367.50M	-776.80M	-778.18M	-4.63B	-1.21B
Operating Cash Flow	-7.70M	173.40M	-273.70M	-1.00M	-4.22B	-1.08B
Investing Cash Flow	-153.90M	-455.70M	649.80M	102.27M	4.30B	12.83B
Financing Cash Flow	-23.00M	33.70M	-26.60M	-28.08M	-183.73M	-11.76B

Panacea Biotec Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price312.95

Price Trends

50DMA368.11Negative

100DMA431.34Negative

200DMA399.83Negative

Market Momentum

MACD-15.50Positive

RSI34.18Neutral

STOCH31.48Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PANACEABIO, the sentiment is Negative. The current price of 312.95 is below the 20-day moving average (MA) of 340.67, below the 50-day MA of 368.11, and below the 200-day MA of 399.83, indicating a bearish trend. The MACD of -15.50 indicates Positive momentum. The RSI at 34.18 is Neutral, neither overbought nor oversold. The STOCH value of 31.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:PANACEABIO.

Panacea Biotec Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:PANACEABIO against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:CONCORDBIO	72Outperform	INR 130.28B	46.20	―	0.61%	4.02%	-12.81%
IN:SUPRIYA	67Neutral	INR 68.10B	34.37	―	0.12%	28.14%	11.38%
IN:PPLPHARMA	56Neutral	INR 318.26B	-151.42	―	0.06%	9.43%	-767.49%
IN:SYNGENE	56Neutral	INR 162.52B	86.98	―	0.31%	-5.99%	-60.30%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:BIOCON	49Neutral	INR 573.10B	103.47	―	0.14%	9.83%	5.07%
IN:PANACEABIO	47Neutral	INR 19.17B	-270.04	―	―	10.26%	-162.02%

* General Sector Average

Performance Comparison

IN:PANACEABIO and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:PANACEABIO	Panacea Biotec Limited	312.95	-119.10	-27.57%
IN:BIOCON	Biocon Limited	352.00	-24.75	-6.57%
IN:CONCORDBIO	Concord Biotech Ltd.	1245.30	-214.11	-14.67%
IN:PPLPHARMA	Piramal Pharma Limited	239.05	37.45	18.58%
IN:SUPRIYA	Supriya Lifescience Limited	846.20	62.38	7.96%
IN:SYNGENE	Syngene International Ltd.	402.60	-253.29	-38.62%

Panacea Biotec Limited Corporate Events

Panacea Biotec Publishes Q1 FY2026 Unaudited Results in Newspapers

Aug 14, 2026

Panacea Biotec Limited has notified the stock exchanges that it has published extracts of its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 in Business Standard and Desh Sewak newspapers, in compliance wi...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 11, 2026

Panacea Biotec Limited AI Stock Analysis